ATE318598T1 - Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen - Google Patents
Antioxidierende stabilisierungssysteme für pharmazeutische formulierungenInfo
- Publication number
- ATE318598T1 ATE318598T1 AT98958610T AT98958610T ATE318598T1 AT E318598 T1 ATE318598 T1 AT E318598T1 AT 98958610 T AT98958610 T AT 98958610T AT 98958610 T AT98958610 T AT 98958610T AT E318598 T1 ATE318598 T1 AT E318598T1
- Authority
- AT
- Austria
- Prior art keywords
- pharmaceutical formulations
- preferred
- carboxylic acid
- chemically stable
- stable pharmaceutical
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 239000003963 antioxidant agent Substances 0.000 title abstract 4
- 230000003078 antioxidant effect Effects 0.000 title abstract 2
- 230000006641 stabilisation Effects 0.000 title 1
- 238000011105 stabilization Methods 0.000 title 1
- 235000006708 antioxidants Nutrition 0.000 abstract 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000001735 carboxylic acids Chemical class 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 abstract 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229960005070 ascorbic acid Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 abstract 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 abstract 1
- 125000002843 carboxylic acid group Chemical group 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 150000003840 hydrochlorides Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/057,260 US5962488A (en) | 1998-04-08 | 1998-04-08 | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE318598T1 true ATE318598T1 (de) | 2006-03-15 |
Family
ID=22009506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98958610T ATE318598T1 (de) | 1998-04-08 | 1998-11-16 | Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US5962488A (enExample) |
| EP (1) | EP1067927B1 (enExample) |
| JP (1) | JP2003522724A (enExample) |
| AT (1) | ATE318598T1 (enExample) |
| CA (1) | CA2327708A1 (enExample) |
| DE (1) | DE69833684T2 (enExample) |
| WO (1) | WO1999052529A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5962488A (en) * | 1998-04-08 | 1999-10-05 | Roberts Laboratories, Inc. | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
| KR20010101631A (ko) * | 1999-01-21 | 2001-11-14 | 시오노 요시히코 | 페놀성 히드록시 화합물의 변색이 저해되는 의약 조성물 |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| JPWO2007046411A1 (ja) * | 2005-10-19 | 2009-04-23 | 大日本住友製薬株式会社 | イソキサゾール化合物の安定化方法 |
| DE102007025275A1 (de) * | 2007-05-31 | 2008-12-04 | Qiagen Gmbh | Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe |
| AU2009207796B2 (en) | 2008-01-25 | 2014-03-27 | Grunenthal Gmbh | Pharmaceutical dosage form |
| KR101690094B1 (ko) | 2008-05-09 | 2016-12-27 | 그뤼넨탈 게엠베하 | 분무 응결 단계의 사용하에 중간 분말 제형 및 최종 고체 제형을 제조하는 방법 |
| UY32008A (es) * | 2008-07-28 | 2010-02-26 | Takeda Pharmaceutical | Composición farmacéutica |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| ES2428938T3 (es) * | 2009-07-22 | 2013-11-12 | Grünenthal GmbH | Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación |
| RU2604676C2 (ru) | 2010-09-02 | 2016-12-10 | Грюненталь Гмбх | Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль |
| PL2611425T3 (pl) | 2010-09-02 | 2014-09-30 | Gruenenthal Gmbh | Odporna na ingerencję postać dawki zawierająca polimer anionowy |
| HRP20171458T1 (hr) | 2011-07-29 | 2017-11-17 | Grünenthal GmbH | Tableta otporna na mijenjanje koja pruža neposredno oslobađanje lijeka |
| PL2736495T3 (pl) | 2011-07-29 | 2018-01-31 | Gruenenthal Gmbh | Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku |
| WO2013127831A1 (en) | 2012-02-28 | 2013-09-06 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| LT2838512T (lt) | 2012-04-18 | 2018-11-12 | GrĆ¼nenthal GmbH | Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| AR096438A1 (es) | 2013-05-29 | 2015-12-30 | Gruenenthal Gmbh | Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| JP6480936B2 (ja) | 2013-11-26 | 2019-03-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | クライオミリングによる粉末状医薬組成物の調製 |
| JP2017518980A (ja) | 2014-05-12 | 2017-07-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールを含む、改変防止即時放出カプセル製剤 |
| CN106456550A (zh) | 2014-05-26 | 2017-02-22 | 格吕伦塔尔有限公司 | 避免乙醇剂量倾泻的多颗粒 |
| KR20170139158A (ko) | 2015-04-24 | 2017-12-18 | 그뤼넨탈 게엠베하 | 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태 |
| CN107750159B (zh) * | 2015-06-23 | 2021-10-29 | 英特维特国际股份有限公司 | 用于消毒的饮用水的含有维生素的异噁唑啉溶液 |
| WO2017042325A1 (en) | 2015-09-10 | 2017-03-16 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| MX2023003783A (es) * | 2020-10-01 | 2023-04-26 | Imago Biosciences Inc | Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB679192A (en) * | 1948-07-09 | 1952-09-17 | Eastman Kodak Co | Method of stabilizing fats and fatty oils against oxidation |
| GB682205A (en) * | 1949-03-16 | 1952-11-05 | Eastman Kodak Co | Improvements in and relating to anti-oxidants for oils and fats |
| US4091091A (en) * | 1973-11-08 | 1978-05-23 | Eli Lilly And Company | Stabilized nitroglycerin tablets |
| JPS5299242A (en) * | 1976-02-12 | 1977-08-19 | Tanabe Seiyaku Co | Antiioxidant |
| JPS62153385A (ja) * | 1985-12-27 | 1987-07-08 | Riken Vitamin Co Ltd | 酸化防止剤 |
| US4837031A (en) * | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
| CA1335106C (en) * | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| US5420151A (en) * | 1989-12-22 | 1995-05-30 | Aktiebolaget Astra | Chroman derivatives |
| DK0471515T3 (da) * | 1990-08-15 | 1997-07-21 | Lilly Co Eli | Ringsubstituerede 2-amino-1,2,3,4-tetrahydronphtalener, 3-aminochromaner og 3-aminothiochromaner |
| JPH06500594A (ja) * | 1991-01-07 | 1994-01-20 | カビ ファルマシア アクチェボラーグ | 多不飽和油の安定化のための天然酸化防止剤の組成物 |
| US5077069A (en) * | 1991-01-07 | 1991-12-31 | Kabi Pharmacia Ab | Composition of natural antioxidants for the stabilization of polyunsaturated oils |
| JPH05339154A (ja) * | 1992-06-03 | 1993-12-21 | Sagami Chem Res Center | 肝機能改善剤 |
| US5434174A (en) * | 1992-07-17 | 1995-07-18 | Eli Lilly And Company | Isoxazole derivatives for the treatment of irritable bowel syndrome |
| JPH0717855A (ja) * | 1992-09-02 | 1995-01-20 | Maruha Corp | 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品 |
| PT725639E (pt) * | 1993-10-25 | 2001-02-28 | Merrell Pharma Inc | Composicao farmaceutica estavel de terfenadina e ibuprofeno |
| JPH09194362A (ja) * | 1996-01-19 | 1997-07-29 | Bizen Kasei Kk | ドコサヘキサエン酸及びエイコサペンタエン酸含有リン脂質を含む組成物 |
| JP3941073B2 (ja) * | 1996-03-01 | 2007-07-04 | 日本油脂株式会社 | 油脂組成物及びそれを含む食品 |
| US5962488A (en) * | 1998-04-08 | 1999-10-05 | Roberts Laboratories, Inc. | Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives |
-
1998
- 1998-04-08 US US09/057,260 patent/US5962488A/en not_active Expired - Fee Related
- 1998-11-16 DE DE69833684T patent/DE69833684T2/de not_active Expired - Fee Related
- 1998-11-16 CA CA002327708A patent/CA2327708A1/en not_active Abandoned
- 1998-11-16 AT AT98958610T patent/ATE318598T1/de not_active IP Right Cessation
- 1998-11-16 EP EP98958610A patent/EP1067927B1/en not_active Expired - Lifetime
- 1998-11-16 JP JP2000543139A patent/JP2003522724A/ja active Pending
- 1998-11-16 WO PCT/US1998/024471 patent/WO1999052529A1/en not_active Ceased
-
1999
- 1999-04-12 US US09/290,904 patent/US6479529B1/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE69833684D1 (de) | 2006-04-27 |
| WO1999052529A1 (en) | 1999-10-21 |
| US5962488A (en) | 1999-10-05 |
| EP1067927A4 (en) | 2003-04-23 |
| US6479529B1 (en) | 2002-11-12 |
| EP1067927A1 (en) | 2001-01-17 |
| DE69833684T2 (de) | 2006-11-16 |
| CA2327708A1 (en) | 1999-10-21 |
| JP2003522724A (ja) | 2003-07-29 |
| EP1067927B1 (en) | 2006-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69833684D1 (de) | Antioxidierende stabilisierungssysteme für pharmazeutische formulierungen | |
| ZA200501715B (en) | Solution for ungual application | |
| EA200400730A1 (ru) | Ингалятор контролируемой дозы | |
| RU2009112207A (ru) | Конкретное глюкокортикостероидное соединение, обладающее противовоспалительной активностью | |
| DE69418468D1 (de) | Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen | |
| ATE448194T1 (de) | Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts | |
| CA2108903A1 (en) | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | |
| DE60317039D1 (de) | Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben | |
| BR0311460A (pt) | Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente | |
| ATE218868T1 (de) | Hustenhemmende, theobromine enthaltende zusammensetzungen | |
| MD1688F2 (en) | Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection | |
| JPS617252A (ja) | 安定化された透明過酸化ベンゾイル組成物 | |
| DE60022895D1 (de) | Pdgf-rezeptor-kinase hemmende verbindungen, deren herstellung, reinigung und diese verbindungen enthaltende pharmazeutische zusammensetzungen | |
| IT1251166B (it) | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono | |
| BR9106367A (pt) | Acidos e n-hidroxiureias anti-inflamatorias | |
| ES2106531T3 (es) | Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso. | |
| EA199901012A1 (ru) | Фармацевтические композиции на основе тизоксанида и нитазоксанида | |
| NO912414L (no) | Forbindelse med mavesyreinhiberende effekt og fremgangsmaate for dens fremstilling. | |
| NO932843D0 (no) | Farmasoeytiske preparater | |
| IE781425L (en) | Injectable chloroamphenicol solution | |
| DE3476160D1 (en) | Derivatives of benzoic acid for use as a medicament and use of these derivatives as conserving or disinfecting agent | |
| FI932654A0 (fi) | Hydroxamsyraderivat, som hindrar lipoxigenas | |
| DE69414396D1 (de) | Acylphenylglycin-derivat und dieses als aktivbestandteil enthaltendes vorbeugungs -und heilmittel gegen durch erhöhte collagenaseaktivität verursachte krankheiten | |
| DK1100463T3 (da) | Injicerbare formuleringer indeholdende ramoplanin | |
| CA1142090A (en) | Topical anti-inflammatory composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |